ID helix-loop-helix proteins as determinants of cell survival in B-cell chronic lymphocytic leukemia cells in vitro

Molecular Cancer

Volumn 14, Issue 1, 2015, Pages

  Weiler, Sarah ^a   Ademokun, Jolaolu A ^b   Norton, John D ^a  

^a UNIVERSITY OF ESSEX   (United Kingdom)

^b IPSWICH HOSPITAL NHS TRUST   (United Kingdom)

Author keywords

Cell survival cell death; Chronic lymphocytic leukemia; Drug resistance; ID helix loop helix proteins

Indexed keywords

CHLORAMBUCIL; DNA BINDING PROTEIN; EOTAXIN; ETACRYNIC ACID; FLUDARABINE; GLUTATHIONE; HELIX LOOP HELIX PROTEIN; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 4; MONOCYTE CHEMOTACTIC PROTEIN 5; SMALL INTERFERING RNA; THYMUS AND ACTIVATION REGULATED CHEMOKINE; BASIC HELIX LOOP HELIX TRANSCRIPTION FACTOR; ID2 PROTEIN, HUMAN; ID3 PROTEIN, HUMAN; INHIBITOR OF DIFFERENTIATION 2; INHIBITOR OF DIFFERENTIATION PROTEIN; TUMOR PROTEIN;

APOPTOSIS; ARTICLE; B CELL LEUKEMIA; CELL DEATH; CELL ISOLATION; CELL SURVIVAL; CELL VIABILITY; CHRONIC LYMPHATIC LEUKEMIA; COCULTURE; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG RESPONSE; EFFECTOR CELL; GENE; GENE EXPRESSION; GENE REGULATORY NETWORK; HUMAN; ID1 GENE; ID2 GENE; ID3 GENE; IN VITRO STUDY; LEUKEMIA CELL; MICROARRAY ANALYSIS; OXIDATION REDUCTION STATE; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; UPREGULATION; VASCULAR ENDOTHELIUM; WESTERN BLOTTING; B LYMPHOCYTE; BIOLOGY; CELL LINE; GENETICS; HEK293 CELL LINE; METABOLISM; OXIDATION REDUCTION REACTION; PROCEDURES; UMBILICAL VEIN ENDOTHELIAL CELL;

B-LYMPHOCYTES; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; CELL LINE; CELL SURVIVAL; COMPUTATIONAL BIOLOGY; DNA-BINDING PROTEINS; GENE REGULATORY NETWORKS; HEK293 CELLS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; INHIBITOR OF DIFFERENTIATION PROTEIN 2; INHIBITOR OF DIFFERENTIATION PROTEINS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; NEOPLASM PROTEINS; OXIDATION-REDUCTION;

EID: 84928663914     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/s12943-014-0286-9     Document Type: Article

References (64)

1. Norton JD. ID helix-loop-helix proteins in cell growth, differentiation and tumourigenesis. J Cell Sci. 2000;113:3897-905.
2. Ruzinova MB, Benezra R. Id proteins in development, cell cycle and cancer. Trends Cell Biol. 2003;13:410-8.
3. Perk J, Iavarone A, Benezra B. ID family of helix-loop-helix proteins in cancer. Nat Rev Cancer. 2005;5:603-14.
4. Kee BL. E and ID proteins branch out. Nat Rev Immunol. 2009;9:175-84.
5. Hong S-H, Lee J-H, Lee JB, Ji J, Bhatia M. ID1 and ID3 represent conserved negative regulators of human embryonic and induced pluripotent stem cell hematopoiesis. J Cell Sci. 2011;124:1445-52.
6. Klarmann KD, Ji M, Li H, Satyanarayana A, Kim W, Bowers E. Novel targets in myelogenous leukaemia: The Id family of proteins. In myeloid leukaemia - basic mechanisms of leukemogenesis. InTech. Edited by Koschmieder S. 2011. doi:10.5772/28303.
7. Mercer EM, Lin YC, Murre C. Factors and networks that underpin early hematopoiesis. Seminars in Immunol. 2011;23:317-25.
8. Tang R, Hirsch P, Fava F, Lapusan S, Marzac C, Teyssandier I, et al. High Id1 expression is associated with poor prognosis in 237 patients with acute myeloid leukaemia. Blood. 2009;114:2993-3000.
9. Mathas S, Janz M, Hummel F, Hummel M, Wollert-Wulf B, Lusatis S, et al. Intrinsic inhibition of transcription factor E2A by HLH proteins ABF-1 and Id2 mediates reprogramming of neoplastic B cells in Hodgkin lymphoma. Nat Immunol. 2006;7:207-15.
10. Renne C, Martin-Subero JI, Eickernjager M, Hansmann M-L, Kuppers R, Siebert R, et al. Aberrant expression of ID2, a suppressor of B-cell specific gene expression, in Hodgkin's lymphoma. Am J Pathol. 2006;169:655-64.
11. Schmitz R, Young RM, Ceribelli M, Jhavar S, Xiao W, Zhang M, et al. Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics. Nature. 2012;490:116-20.
12. Richter J, Schlesner M, Hoffman S, Kreuz M, Leich E, Burkhardt B, et al. Recurrent mutation of the ID3 gene in Burkitt lymphoma identified by integrated genome, exome and transcriptome sequencing. Nat Genet. 2012;44:1316-20.
13. Love C, Sun Z, Jima D, Li G, Zhang J, Miles R, et al. The genetic landscape of mutations in Bukitt's lymphoma. Nat Genet. 2012;44:1321-5.
14. Yu L, Liu C, Vandeusen J, Becknell B, Dai Z, Wu YZ, et al. Global assessment of promoter methylation in a mouse model of cancer identifies ID4 as a putative tumour- suppressor gene in human leukaemia. Nat Genet. 2005;37:265-74.
15. Bellido M, Aventin A, Lasa A, Estivill C, Carnicer MJ, Pons C, et al. Id4 is deregulated by a t(6;14)(p22;q32) chromosomal translocation in a B-cell lineage acute lymphoblastic leukaemia. Haematologica. 2003;88:994-1001.
16. Russell LJ, Akasaka T, Majid A, Sugimoto K-J, Karran EL, Nagel I, et al. t(6;14)(p22;q32): a new recurrent IGH-translocation involving ID4 in B-cell precursor acute lymphoblastic leukaemia. Blood. 2008;111:387-91.
17. Zenz TD, Mertens R, Kuppers H, Dohner H, Stilgenbauer S. From pathogenesis to treatment of chronic lymphocytic leukemia. Nat Rev Cancer. 2010;10:37-50.
18. Gaidano G, Foa R, Dalla-Favera D. Molecular pathogenesis of chronic lymphocytic leukemia. J Clin Invest. 2012;122:3432-8.
19. Chen S-S, Claus R, Lucas DM, Yu L, Qian J, Ruppert AS, et al. Silencing of the inhibitor of DNA binding protein 4 (ID4) contributes to the pathogenesis of mouse and human CLL. Blood. 2011;117:826-71.
20. Zheng Z, Venkatapathy S, Rao G, Harrington CA. Expression profiling of B cell chronic lymphocytic leukemia suggests deficient CD1-mediated immunity, polarized cytokine response, altered adhesion and increased intracellular protein transport and processing of leukemic cells. Leukemia. 2002;16:2429-37.
21. Jelinek DF, Tschumper RC, Stolovitzky GA, Iturria SJ, Tu Y, Lepre J, et al. Identification of a global gene expression signature of B-chronic lymphocytic leukemia. Mol Cancer Res. 2003;1:346-61.
22. Zhang X, Ling MT, Wong YC, Wang X. Evidence of a novel antiapoptotic factor: role of inhibitor of differentiation or DNA binding (Id-1) in anticancer drug-induced apoptosis. Cancer Sci. 2007;98:308-14.
23. Mallory JC, Crudden G, Oliva A, Saunders C, Stromberg A, Craven RJ. A novel group of genes regulates susceptibility to antineoplastic drugs in highly tumorigenic breast cancer cells. Mol Pharmacol. 2005;68:1747-56.
24. Geng H, Rademacher BL, Pittsenbarger J, Huang CY, Harvey T, Lafortune MC, et al. ID1 enhances docetaxel cytotoxicity in prostate cancer cells through Inhibition of p21. Cancer Res. 2010;70:3239-48.
25. Friedman DR, Lucas JE, Weinberg JB. Clinical and biological relevance of genomic heterogeneity in chronic lymphocytic leukaemia. PLoS One. 2013;8:e57356.
26. Reshef DN, Reshef YA, Finucane HK, Grossman SR, McVean G, Turnbaugh PJ, et al. Detecting novel associations in large data sets. Science. 2011;334:1518-24.
27. Zekavati A, Nasir A, Alcaraz A, Aldrovandi M, Marsh P, Norton JD, et al. Post-transcriptional regulation of BCL2 mRNA by the RNA-binding protein, ZFP36L1 in malignant B cells. PLoS One. 2014;9:e102625.
28. Franceschini A, Szklarczyk D, Frankild S, Kuhn M, Simonovic M, Roth A, et al. STRING v9.1: protein-protein interaction networks, with increased coverage and integration. Nucleic Acids Res. 2013;41:D808-15.
29. Kalathur RK, Pinto JP, Hernández-Prieto MA, Machado RS, Almeida D, Chaurasia G, et al. UniHI 7: an enhanced database for retrieval and interactive analysis of human molecular interaction networks. Nucleic Acids Res. 2014;42:D408-14.
30. Lu D, Liu JX, Endo T, Zhou H, Yao S, Willert K, et al. Ethacrynic acid exhibits selective toxicity to chronic lymphocytic leukemia cells by inhibition of the Wnt/beta-catenin pathway. PLoS One. 2009;4:e8294.
31. Stacchini A, Aragno M, Vallario A, Alfarano A, Circosta P, Gottardi D, et al. MEC1 and MEC2: two new cell lines derived from B-chronic lymphocytic leukaemia in prolymphacytoid transformation. Leukemia Res. 1999;23:127-36.
32. Henrich S, Christopherson RI. Multiple forms of nuclear p53 formed in human Raji and MEC1 cells treated with fludarabine. Leukemia. 2008;22:657-60.
33. Zhang W, Trachootham D, Lui J, Chen G, Pelicano H, Garcia-Prieto C, et al. Stromal control of cystine metabolism promotes cancer cell survival in chronic lymphocytic leukaemia. Nat Cell Biol. 2012;14:276-87.
34. Penella E, Sandoval J, Zaragozá R, García C, Viña JR, Torres L, et al. Molecular mechanisms of Id2 down-regulation in rat liver after acetaminophen overdose. Protection by N-acetyl-L-cysteine Free Rad Res. 2010;44:1044-53.
35. Markovic J, Mora NJ, Broseta AM, Gimeno A, De-la-Concepción N, Viña J, et al. The depletion of nuclear glutathione impairs cell proliferation in 3 t3 fibroblasts. PLoS One. 2009;4:e6413.
36. Koyama T, Suzuki H, Imakiire A, Yanase N, Hata K, Mizuguchi J. Id3- mediated enhancement of Cisplatin-induced apoptosis in a sarcoma cell line MG-63. Anticancer Res. 2004;24:1519-24.
37. Maffei R, Fiorcari S, Bulgarelli J, Martinelli S, Castelli I, Deaglio S, et al. Physical contact with endothelial cells through beta1- and beta2- integrins rescues chronic lymphocytic leukemia cells from spontaneous and drug-induced apoptosis and induces a peculiar gene expression profile in leukemic cells. Haematologica. 2012;97:952-60.
38. Trachootham D, Zhang H, Zhang W, Feng L, Du M, Zhou Y, et al. Effective elimination of fludarabine-resistant CLL cells by PEITC through a redox-mediated mechanism. Blood. 2008;112:1912-22.
39. De Pooter RF, Kee BL. E proteins and the regulation of early lymphocyte development. Immunol Rev. 2010;238:93-109.
40. Wang LL, Lawrence MS, Wan YZ, Stojanov P, Sougnez C, Stevenson K, et al. SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. New Engl J Med. 2011;365:2497-506.
41. Fält S, Merup M, Tobin G, Thunberg U, Gahrton G, Rosenquist R, et al. Distinctive gene expression pattern in VH3-21 utilizing B-cell chronic lymphocytic leukemia. Blood. 2005;106:681-9.
42. Coscia M, Pantaleoni F, Riganti C, Vitale C, Rigoni M, Peola S, et al. IGHV unmutated CLL B cells are more prone to spontaneous apoptosis and subject to environmental prosurvival signals than mutated CLL B cells. Leukemia. 2011;25:828-37.
43. Guarini A, Marinelli M, Tavolaro S, Bellacchio E, Magliozzi M, Chiaretti S, et al. ATM gene alterations in chronic lymphocytic leukemia patients induce a distinct gene expression profile and predict disease progression. Haematologica. 2012;97:47-55.
44. Cramer P, Hallek H. Prognostic factors in chronic lymphocytic leukemia - what do we need to know? Nat Rev Clin Oncol. 2011;8:38-47.
45. Kardava L, Yang Q, St Leger A, Foon KA, Lentzsch S, Vallejo AN, et al. The B lineage transcription factor E2A regulates apoptosis in chronic lymphocytic leukemia (CLL) cells. Int Immunol. 2011;23:375-84.
46. Patel D, Chaudhary J. Increased expression of bHLH transcription factor E2A (TCF3) in prostate cancer promotes proliferation and confers resistance to doxorubicin-induced apoptosis. Biochem Biophys Res Commun. 2012;422:146-51.
47. Kurtova AV, Balakrishnan K, Chen R, Ding W, Schnabl S, Quiroga MP, et al. Diverse marrow stromal cells protect CLL cells from spontaneous and drug-induced apoptosis; development of a reliable and reproducible system to assess stromal cell adhesion- mediated drug resistance. Blood. 2009;114:4441-50.
48. Buggins AG, Pepper C, Patten PE, Hewamana S, Gohil S, Moorhead J, et al. Interaction with vascular endothelium enhances survival in primary chronic lymphocytic leukemia cells via NF-kappaB activation and de novo gene transcription. Cancer Res. 2010;70:7523-33.
49. NCBI Gene Expression Omnibus database. [ http://www.ncbi.nlm.nih.gov/geo ]
50. Smyth GK. Linear models and empirical Bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol. 2004;3:Article 3.
51. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Ser B. 1995;57:289-300.
52. McCall MN, Bolstad BM, Irizarry RA. Frozen robust multiarray analysis (fRMA). Biostatistics. 2010;11:242-53.
53. Coletta A, Molter C, Duque R, Steenhoff D, Taminau J, de Schaetzen V, et al. InSilico DB genomic datasets hub: an efficient starting point for analysing genome-wide studies in GenePattern, Integrative Genomics Viewer, and R/Bioconductor. Genome Biol. 2012;13:R104.
54. Chuang HY, Rassenti L, Salcedo M, Licon K, Kohlmann A, Haferlach T, et al. Subnetwork-based analysis of chronic lymphocytic leukemia identifies pathways that associate with disease progression. Blood. 2012;120:2639-49.
55. Herold T, Jurinovic V, Metzeler KH, Boulesteix AL, Bergmann M, Seiler T, et al. An eight-gene expression signature for the prediction of survival and time to treatment in chronic lymphocytic leukemia. Leukemia. 2011;10:1639-45.
56. Reich M, Liefeld T, Gould J, Lerner J, Tamayo P, Mesirov JP. GenePattern 2.0. Nat Genet. 2006;38:500-1.
57. Taminau J, Meganck S, Lazar C, Steenhoff D, Coletta A, Molter C, et al. Unlocking the potential of publicly available microarray data using inSilicoDb and inSilicoMerging R/Bioconductor packages. BMC Bioinformatics. 2012;12:335.
58. Wilkerson MD, Hayes DN. ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking. Bioinformatics. 2010;26:1572-3.
59. Gene set enrichment on-line database. [ http://www.broadinstitute.org/gsea/index.jsp ]
60. Tabas-Madrid D, Nogales-Cadenas R, Pascual-Montano A. GeneCodis3: a non-redundant and modular enrichment analysis tool for functional genomics. Nucleic Acids Res. 2012;40:W478-83.
61. Smoot ME, Ono K, Ruscheinski J, Wang PL, Ideker T. Cytoscape 2.8: new features for data integration and network visualization. Bioinformatics. 2011;2011(27):431-2.
62. Norton JD, Atherton GA. Coupling of cell growth control and apoptosis functions of Id proteins. Mol Cell Biol. 1998;18:2371-81.
63. VassarStats: website for statistical computation. [ http://vassarstats.net/ ]
64. Spitzer M, Wildenhain J, Rappsilber J, Tyers M. BoxPlotR: a web tool for generation of box plots. Nat Methods. 2014;2014(11):121-2.